US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
You may also be interested in...
US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible
New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.
Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.
US FDA Greenlighting Dozens Of New Trials For Coronavirus Therapeutics
In less than three weeks, the number of clinical trials for potential treatments has jumped to 72, according to the FDA’s Coronavirus Treatment Acceleration Program.